Anti-vaccine technology moved out The German government plans to invest 2.4 billion yuan in new crown vaccine developer VacCure

, the German government plans to invest 300 million euros (about 2.4 billion yuan) in VacCure, a new coronavirus vaccine developer, to acquire a 23 percent stake in the company, foreign media reportedThe two sides issued a joint statement saying that the funds will be used by CureVac to further develop the company's proprietary pipeline and mRNA platform technology and expand business activitiesCureVac is a German biotech company founded in 2000, headquartered in Tubingen, Germany, with branches in Frankfurt and Boston, USAIn the field of vaccine development, CureVac is a strong company with several different technology platforms, from stimulating the immune system to using messenger RNA-induced cells to produce targeted protein therapies, and has over 20 years of expertise in processing, optimizing and manufacturing this versatile molecule for medical purposesthe Reason for the German government's big investment, mainly because of previous rumors that the USgovernment is eager to buy the pharmaceutical company's scientific research exclusive rights, at all costs, and even opened a high priceAt the time of the "rumours" that the European Commission president, the vice-president of the European Investment Bank and others had a video conference with CureVac management, which will receive an 80 million euro loan from the European Investment Bank to rapidly expand vaccine development and production at the time of the "mRNA VaccineRace"The German government has also been in close communication with CureVaclater, CureVac denied the "acquisition" of the newsnow appear to have the German government to show the sincerity of its real money in order to keep CureVacAccording to media reports, a letter from the German finance ministry showed that the 300 million euro investment in CureVac was "extremely urgent" because the company was planning to list on NASDAQ in mid-July"The federal government's acquisition of a stake in CureVac is designed to ensure that the company is not being merged by foreign capital and will not leave Germany,"the document saidThe document also states that "there is concern that, once acquired and transferred abroad, a new coronavirus vaccine developed by CureVac in the future will not be available in Germany and Europe." "
this is clearly unacceptable and confronted by the German government on the partnership, German Economy Minister Peter Altmaier said: "CureVac's technology has the potential to develop ground-breaking new vaccines and treatments that are available to many people and are available to the market The German government decided to invest in the promising company in the hope of helping it accelerate its development plans and providing VacCure with the means to make the most of its technological potential "
"We want to give the company financial security", "for me and the federal government, from an industry perspective, it is fundamental that we maintain and strengthen the key industries in Germany", "we (Germany) keep the seller." "
it's worth noting that the "three legends of mRNA" - CureVac, Moderna, BioNTech - joined the research and development of the new crown vaccine in unison, and all used relatively fast nucleic acid technology But compared with the high profile of Moderna and BioNTech, CureVac's news is low and progress is relatively slow Of course, CureVac is not yet a public company, and may be part of the factor CureVac's most recent message about the vaccine was announced on May 14th that its candidate vaccine for the new coronavirus (SARS-CoV-2) had achieved positive preclinical results at low doses, and that clinical trials would be conducted in early June and that it was ready to produce "hundreds of millions of doses" per year at its plant in Germany 's half-way through June, there seems to be nothing moving Moderna plans to launch phase III clinical trials in July, and BioNTech's new coronavirus vaccine began human trials in the U.S in May However, it is said that despite similar techniques used, CureVac's vaccine dose is much lower and its mass production will be easier currently, in addition to german government funding, CureVac has received funding from the Epidemic Prevention Innovation Alliance (CEPI), the Bill and Melinda Gates Foundation, and the U.S Department of Defense's Advanced Research Projects Agency (DARPA) for the development of coronavirus vaccines